The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer
Open Access
Abstract
Background/Objectives: There is conflicting data on which factors predict progression events in active surveillance for early prostate cancer. Here, we explored the value of different clinicopathological variables and whether progression endpoint definitions impact predictive utility. Methods: Clinicopathological variables were extracted from the STRATified CANcer Surveillance (STRATCANs) prospective AS database and included biopsy features (core positivity, cancer core length, and percentage core involvement) and MRI features (Likert score, lesion size, and location), as well as baseline PSA density [PSAd] and Cambridge Prognostic Group (CPG). These were tested against AS endpoint definitions of (1) progression to ≥CPG3, (2) any pathological progression and two definitions from the literature, (3) ≥GG3 or change to treatment, and (4) ≥GG4, metastasis or cancer-related mortality. Predictors were assessed using regression analysis. Results: Data from 296 men were included (median age, 66; follow-up, 5 years). Progression per definition (1–4) occurred in 46 (15.5%), 54 (18.2%), 84 (28.4%), and 10 (3.4%) men. In univariate analysis using Definition 1, no biopsy parameter was independently predictive of progression, while the MRI Likert score (p = 0.02) was the only significant imaging parameter. For Definition 2, core positivity (p = 0.003) and MRI Likert score (p = 0.01) were significant predictors in univariate analyses, while for Definition 3, tumour core length (p = 0.005), core positivity (p = 0.002), and MRI Likert score (p = 0.003) were all predictive in univariate analyses. In multivariate analysis, however, the only consistent independent predictor was PSAd, regardless of endpoint definition. No variables predicted Definition 4 progression. Conclusions: AS endpoint selection appears to define which variables predict progression. Using progression to ≥CPG 3 as an unambiguous AS endpoint, neither biopsy nor MRI variables added incremental value in predicting progression. PSAd, however, appears to be a robust and independent generalisable progression predictor.Keywords
Funding Information
- National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312)
This publication has 36 references indexed in Scilit:
- Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort StudyEuropean Urology Oncology, 2025
- Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European StudyEuropean Urology Oncology, 2025
- Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping SurveillanceEuropean Urology Oncology, 2024
- Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up ProtocolEuropean Urology Open Science, 2023
- Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patientsInternational Urology and Nephrology, 2022
- MRI grading for the prediction of prostate cancer aggressivenessEuropean Radiology, 2021
- Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohortEuropean Radiology, 2020
- The pathological upgrading after radical prostatectomy in low‐risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?The Prostate, 2019
- Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy coresWorld Journal of Urology, 2014
- Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (≥12)-core prostate biopsyWorld Journal of Urology, 2008